BTG2: A Potential Drug Target Or Biomarker (G7832)

Target Name: BTG2

NCBI ID: G7832

BTG2

BTG2: A Potential Drug Target Or Biomarker

BTG2 (NGF-inducible anti-proliferative protein PC3) is a protein that is expressed in various tissues and cells, including the nervous system, and has been shown to play a role in the development and progression of various diseases, including cancer. As a As a result, BTG2 has generated a lot of interest as a potential drug target or biomarker.

BTG2 is a member of the BTG family, which includes several related proteins that are involved in the NGF signaling pathway. This pathway is a critical signaling pathway that regulates cell proliferation, differentiation, and survival, and is involved in the development and progression of many diseases, including cancer.

BTG2 is a 21-kDa protein that is expressed in various tissues and cells, including the nervous system, muscle, heart, and liver. It is composed of a 146 amino acid protein that consists of two distinct domains: an N-terminal domain and a C-terminal domain. The N-terminal domain is rich in conserved charge and structure, while the C-terminal domain is rich in conserved cysteine 鈥嬧?媟esidues and conserved acidic amino acid residues.

BTG2 has been shown to play a role in the development and progression of various diseases, including cancer. For example, it has been shown to be involved in the regulation of cell proliferation, apoptosis, and angiogenesis. BTG2 has also been shown to be involved. in the regulation of neurotransmitter release and synaptic plasticity, which are important for the function of the nervous system.

In addition to its role in the nervous system, BTG2 has also been shown to be involved in the regulation of other tissues and organs. For example, it has been shown to be involved in the regulation of inflammation, immune response, and metabolism.

As a result of its involvement in the development and progression of various diseases, BTG2 has generated a lot of interest as a potential drug target or biomarker. Several studies have shown that BTG2 can be targeted by small molecules, including inhibitors of its N-terminal domain and C-terminal domain. These inhibitors have been shown to be effective in animal models of cancer and other diseases.

In addition to its potential as a drug target, BTG2 has also been shown to be a potential biomarker for several diseases. For example, it has been shown to be a useful biomarker for the diagnosis and prognosis of breast cancer, as well as for the evaluation of the efficacy of anti-cancer drugs.

BTG2 is also a good candidate as a biomarker for other diseases, such as cardiovascular disease, neurodegenerative diseases, and autoimmune diseases. Its ability to regulate cell proliferation, apoptosis, and angiogenesis makes it a potential biomarker for these diseases as well.

In conclusion, BTG2 is a protein that has been shown to play a role in the development and progression of various diseases, including cancer. Its NGF-inducible properties and its ability to regulate cell proliferation, apoptosis, and angiogenesis make it a potential drug target or biomarker. Further studies are needed to fully understand its role in these diseases and to develop effective treatments.

Protein Name: BTG Anti-proliferation Factor 2

Functions: Anti-proliferative protein; the function is mediated by association with deadenylase subunits of the CCR4-NOT complex. Activates mRNA deadenylation in a CNOT6 and CNOT7-dependent manner. In vitro can inhibit deadenylase activity of CNOT7 and CNOT8. Involved in cell cycle regulation. Could be involved in the growth arrest and differentiation of the neuronal precursors (By similarity). Modulates transcription regulation mediated by ESR1. Involved in mitochondrial depolarization and neurite outgrowth

The "BTG2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BTG2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets